Why Patient Understanding Is Becoming the Standard for Clinical Success
Picture a room that most of us in this industry have sat in. The agenda is full, the team is sharp, and the decisions being made are genuinely important ones. A protocol is taking shape, and everyone around the table is working hard to get it right. What can be missing, not for lack of care but simply because it has not been designed in, is what the person on the other side of that protocol is actually navigating.
Not the diagnosis. The patient’s actual Tuesday morning. Whether it’s the half-day of leave they could not afford, the drive across town, or the quiet calculation of how many more times they can do this before it stops feeling worth it. That version of the story does not live in a data set. It exists in the life being lived around the trial, and it has more influence over whether a programme succeeds than teams are often positioned to see.
We have spent years working to close that distance. What we have come to believe, and seen proven again and again, is that clinical success is no longer defined by scientific efficacy alone. It is defined by how well a treatment fits the human life it is meant to support, and that understanding can be built in deliberately, from the very first decisions.
THE DIFFERENCE BETWEEN PATIENT DATA & PATIENT UNDERSTANDING
Patient data and patient understanding are easy to treat as the same thing. They are related, and both valuable, but they answer entirely different questions. Data tells us what happened, but understanding tells us why it happened and what it felt like to the person it happened to.
A development team can know that a particular protocol has a high screen-failure rate at week six. That is data, and it is useful. Understanding, however, is knowing that week six is when the third unpaid day off work lands, when the travel starts to feel unsustainable, and when the person quietly decides that hope is costing them more than they can spend. Both views describe the same moment. Only one of them tells you what to change from the patient’s perspective.
Teams measure carefully, and they are right to do so. What we have learned from years spent in rooms with patients is that the numbers carry more weight when you can feel the lived experience behind them.
Experience what patient understanding actually feels like
Before reading further, we encourage you to feel what we mean for yourself. Our Interactive Showcase is a free thirty-minute session centered on a real clinical trial experience, and it is the closest thing to a patient’s morning we can offer in a short time.
PATIENT UNDERSTANDING AS A STRATEGIC ASSET
When timelines tighten and budgets compress, patient understanding can look like the kind of commitment that waits for a calmer quarter. We know that pressure well, because we work inside it alongside our clients every week. What the evidence increasingly shows is that understanding belongs in a different category altogether. It is a strategic asset, and it behaves like one.
The evidence is becoming hard to overlook. The Economist Intelligence Unit examined around 4,000 Phase II and Phase III trials and found that drugs developed using patient-centric designs were 19 percentage points more likely to be launched than those developed without them. Recruitment was faster too, taking around four months to enrol 100 participants against seven months for trials overall, and faster still in neurology, oncology, and rare disease. That is not a soft benefit. That is the timeline, cost, and probability of success moving in the right direction at once.
And this is not a standalone case, too. We’ve seen similar results with participants in our experiences, with participants noting better patient recruitment and retention from enhanced trial design. Read our case studies.
The wider productivity picture makes the same case. McKinsey estimates that up to 80% of clinical trials fail to finish on time, and that only about 13% of assets entering Phase I go on to launch. When the odds are already that steep, the experience of the people inside the trial is not a detail to optimise later. It is one of the variables most able to move the outcome.
These pressures are not abstract, either. Around 68% of out-of-pocket development spend goes to clinical trials, and within those trials, the median dropout rate is 11%, rising in some areas. Every one of those departures is a person whose experience the trial might have fit better, and each one also carries a real cost to the timeline and the data. This is where understanding earns its place. It brings the human and financial sides together in the same motion.
More and more companies now track patient-centricity as a return in its own right. Deloitte notes that many follow ROI metrics such as improved recruitment and retention in clinical trials, fewer trial amendments, and greater brand loyalty. The language of the boardroom and the language of the patient are converging, and that is a good thing to see.
WHERE UNDERSTANDING PAYS OFF ACROSS DEVELOPMENT
The return on patient understanding shows up at every stage of development, not just in the clinic. We measure it across the functions we work with, and the pattern is consistent. People come away making more grounded decisions in the work they were already doing.
It begins in discovery and clinical research, where trial design is set years before a participant enrols. In our experiences, 87% of R&D participants have gone on to make patient-focused changes to their work, reshaping protocols, lifting recruitment, and improving retention.
That shift carries into medical affairs, too, where 99% of participants report increased confidence in their stakeholder conversations after the experience. It carries through to commercialisation as well, where the quality of a conversation shapes how a treatment is presented and received. With one client, 85% of the sales force improved their ability to articulate the unmet patient need, and 31% reported an increase in the time HCPs gave them during conversations thirty days after the experience.
The thread from early design to late commercialisation is one and the same. Choices that fit the patient tend to be the ones that work commercially too. Recruitment improves because the trial respects the person’s time, retention improves because the experience earns their trust, and the launch speaks to a life the team recognises.
“In my view, I have experienced no better way to understand the highs and lows for patients. Completely invaluable experience to enrich understanding and empathy.”
Global Brand Director
BUILDING DEVELOPMENT AROUND UNDERSTANDING FROM THE START
The most encouraging shift we see is when teams choose to invest. Patient understanding used to arrive late, brought in to support a launch already underway. More and more, it is moving to the front of the process, where it can shape the foundations from the start. The timing matters because protocols have grown heavier over the past decade. Tufts CSDD research found that, from 2010 to 2020, rising protocol complexity coincided with a steep increase in substantial amendments and dropout. Understanding built in early is the most reliable way we know to keep that complexity in check before it compounds.
Starting there, changes everything downstream. A protocol designed with a real feel for the patient’s day carries fewer amendments, recruits more smoothly, and holds onto its participants. A medical team that has lived a version of the condition speaks with more credibility, and a commercial team that knows the daily reality builds campaigns that resonate. This is what we mean when we talk about patient centricity as a standard for the future. Not a single initiative, but a thread of understanding running through every stage of development, set early and carried all the way to the patient.
We believe the teams that build this in from the start will define what good clinical development looks like over the next decade. Science will always matter enormously. What is changing is the recognition that it only succeeds when it meets a real-life well, and that meeting can be designed from the very first decision.
Join our Interactive Showcase
Deeper insights lead to better outcomes, and the fastest way to feel what that means is to experience it. Our Interactive Showcase is a free thirty-minute session, and this month it is built around a clinical trial experience that lends itself perfectly to everything above.
Join our next session or talk to us about a tailored experience built around your therapy area and the decisions your teams are making right now. We would love to show you what patient understanding can do for your development process.
Frequently Asked Questions
What is the difference between patient data and patient understanding?
Patient data tells you what happened in a trial or a treatment journey. Patient understanding tells you why it happened and what it felt like to the person living it. Both matter. Data gives you precision, and understanding gives that precision direction, so the decisions a team makes are grounded in the reality behind the numbers.
What is the A Life in a Day Interactive Showcase?
It is a free thirty-minute session that gives pharma and healthcare professionals a direct sense of how our immersive patient experience works, and this month it is built around a clinical trial journey. Our full experience runs for up to twenty-four hours and combines a smartphone app, a physical kit of simulation items, and live role-play calls with trained actors.
When in development, should we invest in patient understanding?
As early as possible. Understanding built in at the design stage shapes the foundations of a protocol, which carries fewer amendments, recruits more smoothly, and retains more participants. It still adds value later, yet the teams who start early tend to see the benefit compound across the whole programme and into commercialisation.
What measurable outcomes have clients seen from investing in understanding?
Outcomes include 87% of R&D participants making patient-focused changes to their work, 99% of medical affairs participants reporting increased confidence in stakeholder conversations, and an 85% of the sales force improved their ability to articulate the unmet patient need, and 31% reported an increase in time given by HCPs thirty days after the experience.
